CV Therapeutics to Announce 2007 First Quarter Financial Results on Tuesday, April 24, 2007
April 18 2007 - 5:01PM
PR Newswire (US)
PALO ALTO, Calif., April 18 /PRNewswire-FirstCall/ -- CV
Therapeutics, Inc. (NASDAQ:CVTX) today announced that it will
release first quarter financial results for 2007 after the market
closes on Tuesday, April 24, 2007. Company management will webcast
a conference call at 5:00 p.m. EDT, 2:00 p.m. PDT, on the company's
website. To access the live webcast, please log on to the company's
website at http://www.cvt.com/ and go to the Investor Information
section. Alternatively, domestic callers may participate in the
conference call by dialing (888) 370- 6121, and international
callers may participate in the conference call by dialing (706)
679-7163. Webcast and telephone replays of the conference call will
be available approximately two hours after the completion of the
call through Tuesday, May 1, 2007. Domestic callers can access the
replay by dialing (800) 642-1687, and international callers can
access the replay by dialing (706) 645-9291; the PIN access number
is 2680882. About CV Therapeutics CV Therapeutics, Inc.,
headquartered in Palo Alto, California, is a biopharmaceutical
company focused on applying molecular cardiology to the discovery,
development and commercialization of novel, small molecule drugs
for the treatment of cardiovascular diseases. CV Therapeutics'
approved product, Ranexa(R) (ranolazine extended-release tablets),
is indicated for the treatment of chronic angina in patients who
have not achieved an adequate response with other antianginal
drugs, and should be used in combination with amlodipine,
beta-blockers or nitrates. CV Therapeutics also has other clinical
and preclinical drug development candidates and programs, including
regadenoson, which is being developed for potential use as a
pharmacologic stress agent in myocardial perfusion imaging studies,
and CVT-6883, which is being developed as a potential treatment for
asthma and other conditions. These product candidates have not been
determined by any regulatory authorities to be safe or effective in
humans for any use. Complete prescribing information for Ranexa,
including detailed safety and dosage information are available at
http://www.ranexa.com/. DATASOURCE: CV Therapeutics CONTACT:
investors and media, John Bluth, Senior Director, Corporate
Communications and Investor Relations, +1-650-384-8850 Web site:
http://www.cvt.com/ http://www.ranexa.com/
Copyright
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jul 2023 to Jul 2024